17:20:25 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-14 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-07-31 Extra Bolagsstämma 2024
2024-05-30 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-03-01 X-dag ordinarie utdelning CSMED 0.00 DKK
2024-02-14 Bokslutskommuniké 2023
2023-12-15 X-dag ordinarie utdelning CSMED 0.00 DKK
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-04-14 Extra Bolagsstämma 2023
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 X-dag ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 X-dag ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2024-06-28 12:20:29

Today on June 28, 2024, in Copenhagen - CS MEDICA A/S ("CS MEDICA" or "The Company") held an extraordinary general meeting at which the following principal resolutions were passed.

Authorization for the company's board of directors to list CS MEDICA shares on the German Stock Exchange.

The Extraordinary General Meeting (EGM) resolved in accordance with the Board of Directors' proposal to authorize the company's board of directors to list the company on one of the multilateral trading facilities (MTF) in Germany.

Authorization for the company's board of directors to list the company's subsidiary, CANNORDIC A/S, on the German Stock Exchange via an initial public offering (IPO) at a valuation of DKK 223.5 million (€30 million). Concurrent proposal to increase the number of shares of CANNORDIC A/S from the current 500 units of DKK 1,000 to 5,000,000 units of DKK 0.1, maintaining the same voting rights.

The EGM resolved, in accordance with the Board of Directors' proposal, to approve the listing of the company's subsidiary, CANNORDIC A/S, on one of the multilateral trading facilities (MTF) in Germany via an initial public offering (IPO) at a valuation of DKK 223.5 million (€30 million). Concurrently, the EGM approved the proposal to increase the number of shares of CANNORDIC A/S from the current 500 shares with a nominal value of DKK 1,000 each to 5,000,000 shares with a nominal value of DKK 0.10 each, maintaining the same voting rights.

The total number of votes as of the date of this Statement is 12,322,635, whereof 71,8%, equal to 8,842,160, votes were represented at the EGM.

The resolutions were approved unanimously by all shareholders represented at the EGM.